RBD SARS-CoV-2 HBsAg VLP Vaccine / SpyBiotech, Serum Institute of India, Dynavax 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RBD SARS-CoV-2 HBsAg VLP Vaccine / SpyBiotech, Serum Institute of India, Dynavax
ACTRN12620001308987: A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of a novel Receptor Binding Domain (RBD) COVID-19 Vaccine in Healthy Adults

Terminated
1/2
255
 
Accelagen Pty Ltd, Serum Institute of India Pvt Ltd
SARS-CoV-2, COVID-19
 
 

Download Options